Fin Cascade
Get Android appGet iOS app

Prices as of 9 Oct 2026 close · Not investment advice

Lyka Labs Limited

NSE: LYKALABSPharmaceuticalsTrade-to-trade true

Share price

₹72.65

-0.04% close of 9 Oct 2026

Market cap ₹262 CrP/E —

Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 8 Oct 2026, the close above is 9 Oct 2026.

Business score

How strong the business is, in one number. The parts behind it are in Pro.

31

out of 100 · worked out 9 Oct 2026

How the business score works

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹262 Cr

P/E ratio

—

P/B ratio

2.8

ROCE

-6.0%

ROE

-10.1%

Dividend yield

0.0%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 9 Oct 2026 close52-week high ₹98.3752-week low ₹44.95

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales fell 2.6% over the past year. Meanwhile what it keeps of every 100 rupees of sales slipped from 39.3% to -3.5% over the last four years.

Whether it grew faster than its sector

It grew 1.0% a year against a sector median of 13.1% — 12.1 percentage points slower.

Room to re-rate, or risk of de-rating

It has no earnings, so there is no price-to-earnings to compare.

Whether growth justifies the valuation

It has no earnings to weigh the price against.

Profit growthPrice per ₹1 profitPer 1% growth
Lyka Labs Limited — this one-32%/yr——
Piramal Pharma Limited-31%/yr——
Acutaas Chemicals Limited62%/yr67.1×₹1.1
Rubicon Research Limited155%/yr91.1×—
Granules India Limited5%/yr31.4×₹6.3
Shilpa Medicare Limited107%/yr72.0×—

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 123 of 130 on returns, 112 of 127 on growth, 123 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

It is losing money on the capital in the business, so there is no advantage to measure.

Whether its growth pays for itself

Yes — Over the last five years it made ₹97 crore of cash from the business, spent ₹33 crore on plant and equipment, and returned ₹74 crore to lenders and shareholders. It has not made a profit over 12 years.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

7 of 10 checks clear · 70%

How the profit check works

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Announced 10 Aug 2026 · Consolidated · Unaudited

Revenue

₹42 Cr

Revenue vs last year

+28.1%

Revenue vs last quarter

+50.9%

Net profit

₹2 Cr

Profit vs last year

+106.7%

Net margin

4.8%

EPS

₹0.57

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹262 Cr
Prev close
₹72.65
52w High
₹101
52w Low
₹44.1
Enterprise value
₹309 Cr
Beta
1.1
Price CAGR 1y
-22.0%
Price CAGR 3y
-14.0%
Price CAGR 5y
-1.0%
Price CAGR 10y
1.0%

Ratios

Return on assets
-5.7%
PEG ratio
—
P/E ratio
—
P/B ratio
2.8
EV / EBITDA
—
Industry P/E
37.6
ROCE
-6.0%
ROCE 5y average
14.8%
ROE
-10.1%
Debt / Equity
0.5
Interest coverage
-3.0
Dividend yield
0.0%
ROE 3y average
-2.0%
ROE last year
-10.0%

Annual P&L

Annual revenue
₹128 Cr
Annual profit
-₹10 Cr
Operating margin
-2.7%
Net profit margin
-7.8%
EBITDA margin
-2.3%
Sales growth 3y
11.2%
Sales growth 5y
8.3%
Profit growth 3y
-32.0%
Profit growth 5y
1.0%
EPS
₹-2.8
Sales growth TTM
-3.0%
Profit growth TTM
-219.0%
Dividend payout
0.0%

Quarter P&L

Sales latest quarter
₹42 Cr
Profit latest quarter
₹2 Cr
YoY quarterly sales growth
28.1%
YoY quarterly profit growth
107.1%
OPM latest quarter
10.8%

Balance Sheet

Book Value
₹25.8
Face Value
₹10.0
Total debt
₹49 Cr
Total cash
₹1 Cr
Borrowings
₹49 Cr
Reserves / Equity
1.6

Cash Flow

Operating cash flow
₹5 Cr
Free cash flow
-₹6 Cr
FCF yield
-3.4%
Net cash flow
₹0 Cr

Shareholding

Promoter holding
58.5%
FII holding
0.2%
DII holding
0.7%
Public holding
40.7%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,787.0033.94,28,7610.902,901.26.015,299.910.520.5
Divi's Lab.9,548.5085.02,53,4830.31902.065.53,080.027.822.0
Torrent Pharma.4,709.3080.31,79,1270.81566.05.84,921.054.915.2
Zydus Lifesci.1,144.3023.41,14,1440.09990.2-35.18,017.022.021.1
Laurus Labs2,043.70101.01,10,4240.10362.1125.52,026.329.117.8
Cipla1,325.7529.91,07,1030.98785.6-39.27,119.32.315.5
Mankind Pharma2,470.1047.81,02,0260.04574.129.64,030.612.913.5
Lyka Labs73.152640.002.1122.642.328.1-6.0
Median415.1034.72,1640.0713.229.6162.418.615.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales23283328304134333337312842
Expenses20242626263629292939293438
Material Cost8.977.337.4311
Change in Inventories0.23-0.08-1.39-2.26
Purchases of Stock-in-Trade5.674.305.007.50
Employee Cost109.491311
Other Expenses148.04119.82
Operating Profit2.644.176.872.023.714.955.194.083.68-2.541.65-6.454.55
OPM %1215217.271212151211-6.935.37-2311
Other Income0.38-0.180.540.320.560.030.830.820.631.091.160.610.42
Exceptional items (within Other Income)0000
Interest1.351.191.281.070.650.540.610.470.850.790.820.701.01
Depreciation3.473.592.842.901.761.761.831.422.112.152.152.042.01
Profit before tax-1.80-0.793.29-1.631.862.683.583.011.35-4.39-0.16-8.581.95
Tax %7.22-2339283128243327-27-6.25-6.06-5.13
Net Profit-1.85-0.491.78-2.091.291.912.702.030.99-3.22-0.15-8.072.05
EPS in Rs-0.56-0.150.54-0.630.400.590.760.500.26-0.940-2.130.57
Diluted EPS in Rs-0.940-2.130.57

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemJun 2015Mar 2016 9mMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales1661301106071618619493111138128138
Expenses1391108763736567937695121132141
Material Cost32
Change in Inventories-1.08
Purchases of Stock-in-Trade20
Employee Cost42
Other Expenses40
Operating Profit282023-4-2-420101171618-3-3
OPM %171621-6-2.70-62352181413-2.70-2
Other Income48-241-300-4-41243
Exceptional items (within Other Income)0
Interest241519107202620125233
Depreciation1191011788171413788
Profit before tax-34-8-20-15-62-1459-13-111-12-11
Tax %31-5-19-5-591-2935-018229-11
Net Profit-54-7-19-6-63-1038-13-38-10-9
EPS in Rs-2.291.67-2.51-6.14-1.97-21-4.0314-4.30-0.752.24-2.81-2.50
Diluted EPS in Rs-2.81
Dividend Payout %000000000000

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
-0%
5 years
8%
3 years
11%
TTM
-3%

Compounded profit growth

10 years
—
5 years
1%
3 years
-32%
TTM
-219%

Stock price CAGR

10 years
1%
5 years
-1%
3 years
-14%
1 year
-22%

Return on equity

10 years
—
5 years
—
3 years
-2%
Last year
-10%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemJun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital222222282829292931333636
Reserves2022162115-43-54-1515356957
Borrowings1371211261139614116313075593949
Other Liabilities1007788677673524231303233
Minority Interest-1.56
Total Liabilities279242252229216200190186152157176175
Fixed Assets122104133116108105989468588587
CWIP2730242831282618162312
Investments000000000000
Other Assets13010794857768667467769086
Total Assets279242252229216200190186152157176175

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemJun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity27123111275979921.905
Cash from Investing Activity3717-13-3-4-0-0-67-9-12-9
Cash from Financing Activity-60-30-19-10-233-12-63-22254
Net Cash Flow4-1-0-3-19-310-5-6-50
Free Cash Flow552818723487215-7-10-6

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemJun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days12412197125754837357989114100
Inventory Days7756901396569415668788299
Days Payable22021826630121619214196919898122
Cash Conversion Cycle-18-41-79-37-75-76-63-555689776
Working Capital Days-220-242-357-735-265-242-118-121-0235123
ROCE %1079-8-5-610615410-6

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters555555585858585858585858
FIIs0.180.170.170.150.150.150.240.160.170.170.290.17
DIIs0.410.620.810.750.660.660.660.660.660.660.660.66
Public454444414141414141414141
No. of Shareholders26,65226,42225,71725,71628,94329,09928,47228,18927,74327,15526,72729,369

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year -23.1% (₹94.44 → ₹72.65)Brick size ₹2.29 (fixed)Bricks 60
₹60.00₹80.00₹72.65Nov '25Jan '26Mar '26May '26Jul '26Sep '26
Price moved up one brickPrice moved down one brickLast close ₹72.65 on 9 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

47.61inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

News

News and filings about Lyka Labs Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • critical injectable-grade raw material imported for lyophilisation
  • pharmaceutical raw materials and packing materials
  • purchased pharmaceutical stock-in-trade

Sells to

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE933A01014

Plants

  • Lyka Labs Ankleshwar Plant · Ankleshwar, Gujarat

News impact

Big market events that reach Lyka Labs Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Splits, bonuses & buybacks

  • daily-prices repair: 8 rows from NSE's archive (replace 1, delete 0, insert 7), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.